Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

This is an open label randomized phase II trial of maintenance oral etoposide vs. observation in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).

Trial Details

NCT ID
NCT04804007
Phase
PHASE2
Sponsor
Nabil Adra
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Etoposide
Locations (sample)
  • Indianapolis, Indiana, United States|39.76838,-86.15804

Key Eligibility Criteria

  • Written informed consent and HIPAA authorization for release of personal health information
  • Age ≥ 18 years at the time of consent
  • Histological or serological evidence of non-seminomatous GCT
  • Relapsed disease after first-line cisplatin-based combination chemotherapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →